Cellyrix Therapeutics
TargetingTumor Heterogeneity
Startup Pre-Funding Health Tech & Life Sciences Est. 2024
Total Raised
Undisclosed
Pre-Funding
Last Round
Undisclosed
Team
3
1-10 employees
Confidence
75/100
About
At Cellyrix, we are on a mission to introduce a new modality into cancer treatment by harnessing the power of cutting-edge technologies. Tumor heterogeneity, a fundamental aspect of cancer, lies at the heart of treatment challenges such as therapy resistance, metastasis, and relapse. Leveraging breakthroughs in single-cell sequencing and artificial intelligence, we are pioneering a novel approach to unlock insights into intra-tumor heterogeneity and develop innovative cancer treatments.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Core Technology
Artificial IntelligenceGenerative AIBiologicalsMolecules
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business Model
B2B
Tags
drug-discoverycancer-therapypharmaceuticalsdrug-developmentcancerbiotechnologyartificial-intelligence
Details
Product Stage
R&D
Employees
1-10
Exact Count
5
District
Center District
Founded
2024
Registrar
517076782
Locations
Rehovot, Israel
Links
LinkedIn
Admin
Last Update
Jan 7, 2025
Verified by
Yanina Wainscheinker
Claimed
Yes
Missing
sector, homepage, video or image, funding rounds, news, markets, not claimed
Team (3)
Mordechai Applebaum
CEO
Founder
Dganit Bar
CSO
Founder
Avishai Gavish
Chief Business Consultant
Founder
Internal
Created by
Mordechai (cellyrix@gmail.com)
Created
2024-11-09T00:00:00.000Z